Floatz logo

7 assets in Squamous Cell Carcinoma Of Penis

Therapeutic assets addressing Squamous Cell Carcinoma Of Penis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Squamous Cell Carcinoma Of Penis
Institute of Cancer Research, United KingdomP3B (60)
Isocyclophosphamide
Squamous Cell Carcinoma Of Penis
Institute of Cancer Research, United KingdomP3B (60)
Nivolumab
Squamous Cell Carcinoma Of Penis
National Cancer Institute (NCI)P2B (60)
Ipilimumab
Squamous Cell Carcinoma Of Penis
National Cancer Institute (NCI)P2B (59)
Atezolizumab
Squamous Cell Carcinoma Of Penis
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Squamous Cell Carcinoma Of Penis
National Cancer Institute (NCI)P1CC (43)
Evolve104
Squamous Cell Carcinoma Of Penis
EvolveImmune United, IncP1CC (43)